Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immatics N.V. (IMTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ. Immatics files annual reports under Form 20‑F and furnishes current information on Form 6‑K, giving investors structured insight into its clinical programs, collaborations and financial position.
Recent Form 6‑K reports describe interim financial results, business updates and detailed clinical data for Immatics’ PRAME‑focused pipeline. These filings include summaries of Phase 1a and 1b trials for the second‑generation PRAME cell therapy IMA203CD8 in solid tumors, the IMA402 PRAME TCR Bispecific, and the IMA401 MAGEA4/8 TCR Bispecific, along with information on tolerability, response rates, disease control and progression‑free survival in heavily pretreated patient populations. Other 6‑K submissions incorporate interim reports for quarterly periods, outlining revenue from collaboration agreements, research and development expenses, cash position and changes in share capital.
On this page, users can review Immatics’ furnished reports to understand how the company characterizes its PRAME franchise, its TCR Bispecific (TCER®) platform and its strategic collaborations with partners such as Moderna, Bristol Myers Squibb and Genmab. The filings also document corporate developments, including leadership appointments and pipeline prioritization decisions.
Stock Titan enhances these filings with AI‑powered summaries that highlight key clinical and financial points from lengthy documents, helping readers quickly identify material updates. Real‑time ingestion from EDGAR means new Immatics 6‑K and 20‑F submissions appear promptly, and investors can also monitor incorporated exhibits such as press releases and investor presentations referenced in the filings.
Immatics N.V. Chief Development Officer Carsten Alexander Johannes Reinhardt filed a Form 3 reporting his initial ownership in the company. He holds 47,781 Ordinary Shares directly, a series of stock options to buy additional Ordinary Shares at exercise prices ranging from $1.06 to $11.00 with expirations between 2027 and 2036, and 40,000 restricted stock units that vest in four equal annual installments beginning on January 8, 2026.
Immatics N.V. Chief Medical Officer Cedrik Michael Britten has filed an initial Form 3 detailing his equity holdings in the company. The filing lists multiple stock options to buy Ordinary Shares at exercise prices between $8.0600 and $11.0000, with expirations ranging from 2030-06-01 to 2036-01-07. Individual grants include, for example, options over 255,000 underlying Ordinary Shares at an exercise price of $10.0000 expiring on 2030-06-30, and options over 200,000 underlying Ordinary Shares at an exercise price of $9.3200 expiring on 2036-01-07. Footnotes describe vesting schedules, including options that are fully vested and others that vest over four-year periods. The filing also reports 50,000 restricted stock units, each convertible into one Ordinary Share, and 250 Ordinary Shares held directly. This Form 3 records existing positions and does not show any new purchases or sales.
Immatics N.V. filed an initial Form 3 for General Counsel Edward A. Sturchio Jr., detailing his equity-based holdings. The filing lists multiple stock options to buy Ordinary Shares with exercise prices ranging from $8.06 to $12.92 and expirations between 2030 and 2036. It also discloses restricted stock units covering 40,000 Ordinary Shares, which vest in four equal annual installments starting on January 8, 2026. Some options are already fully vested, while others vest over time based on market capitalization performance hurdles and service-based schedules.
Immatics N.V. executive Jordan Zeik Silverstein, Head of Strategy, reported his beneficial holdings of the company’s securities. The filing lists multiple stock option awards over Ordinary Shares at exercise prices ranging from $1.1700 to $11.0000, with expirations from 2028 through 2036, alongside 50,000 restricted stock units and 7,826 Ordinary Shares held directly. Footnotes explain that one option grant is fully vested and others, as well as the RSUs, vest in scheduled installments over several years.
Immatics N.V. director and Chief Executive Officer Harpreet Singh Jasuja filed an initial ownership report showing a mix of ordinary shares, stock options and restricted stock units. He directly holds 217,241 ordinary shares and multiple option grants over ordinary shares with exercise prices ranging from $1.06 to $11.00, plus 167,500 RSUs that each convert into one ordinary share as they vest over time.
Immatics N.V. director Alise Reicin reported existing holdings of stock options in the company. The filing shows options to buy 60,000 ordinary shares at an exercise price of $12.08 per share, expiring on July 28, 2034, vesting in 12 equal quarterly installments over 36 months from the grant date of July 29, 2024. It also lists options to buy 41,500 ordinary shares at an exercise price of $5.44 per share, expiring on June 23, 2035, which vest 100% on the first anniversary of the grant date, June 24, 2025. These entries describe current derivative holdings rather than new open‑market purchases or sales.
Immatics N.V. reported the initial beneficial ownership of its Chief Financial Officer, Ramanan Venkat, in a Form 3. He holds a stock option to buy 350,000 ordinary shares at an exercise price of $9.0000 per share, expiring on September 30, 2035.
These options vest 25% on the first anniversary of the grant date, October 1, 2025, with the remaining 75% vesting in 12 equal quarterly installments over the following three years. The filing shows this option position as a direct holding and does not report any open-market buying or selling activity.
Immatics N.V. director Eliot Forster reported his initial holdings of stock options on a Form 3. The filing lists several option grants giving him the right to buy Immatics ordinary shares at exercise prices between $5.44 and $12.00, with expirations from 2030 through 2035.
According to the footnotes, some of these options are already fully vested, while others vest 100% on the first anniversary of their grant date on June 24, 2025. All positions shown are direct holdings and represent unexercised options, not recent market purchases or sales.
Immatics N.V. Chief People Officer Amie Elizabeth Krause reported her initial ownership of stock options in the company. The filing shows a stock option to buy ordinary shares at an exercise price of $10.58 per share, covering 211,000 underlying ordinary shares.
The options vest 25% on the first anniversary of the grant date, October 27, 2025, and then continue vesting in 12 equal quarterly installments over the following three years, and expire on October 26, 2035. This Form 3 does not reflect any buy or sell transaction, only existing derivative holdings.
Immatics N.V. director Heather L. Mason filed an initial ownership report listing existing stock option awards over the company’s ordinary shares. She holds several options with exercise prices such as 5.4400 and 12.0000 per share, expiring between 2030 and 2035. Some options are already fully vested, while others vest 100% on June 24, 2025, highlighting her long-term equity-based compensation. The filing reports holdings only and does not show any new purchases or sales.